Plasma protein profiling can help detect cancer in patients with non-specific symptoms

A simple blood test can help detect cancer in patients with non-specific symptoms such as fatigue, pain or weight loss. This is according to a Swedish study from Karolinska Institutet, Danderyd Hospital and others, published in Nature Communications.

When patients seek care for non-specific symptoms such as fatigue, pain or weight loss, it is often difficult to determine whether the cause is cancer, another serious condition or something completely harmless. In a new study, researchers at Karolinska Institutet and Danderyd Hospital, together with örebro University, KTH Royal Institute of Technology and SciLifeLab at Uppsala University, have investigated whether proteins in the blood can provide early clues.

Protein signature linked to cancer

The study analzed blood samples from nearly 700 patients referred to the Diagnostic Centre at Danderyd Hospital and örebro University Hospital in Sweden. The samples were taken before the diagnostic investigation began. Using proteomics, a method for large-scale protein analysis, the levels of 1,463 different proteins in plasma were measured. The researchers identified a specific combination of proteins, known as a protein signature, that could be linked to a cancer diagnosis.

"The study shows the potential of large-scale proteomics for extracting clinically relevant information from small amounts of blood," says Mikael Åberg, associate professor at Uppsala University and head of SciLifeLab Affinity Proteomics Uppsala, where the analyses were performed.

Distinguish cancer from other conditions

The researchers then developed a model that can distinguish patients with cancer from those with other conditions, such as inflammatory, autoimmune or infectious diseases, with high precision.

"A particular strength of the study is that the control group consisted largely of patients with other serious conditions that can cause symptoms similar to cancer," says Charlotte Thålin, senior physician at Danderyd Hospital, adjunct professor at Karolinska Institutet and principal investigator for the study.

"This reflects the clinical reality, where patients with non-specific symptoms are often difficult to assess."

Does not replace other methods

The researchers emphasize that the method should not replace imaging diagnostics or biopsies, but rather serve as a support for prioritizing which patients should be investigated further.

The method could help identify which patients should be prioritised for further diagnostics, for example with PET-CT, while avoiding unnecessary investigations in patients without cancer." 

Fredrika Wannberg, resident at Danderyd Hospital and doctoral student at Karolinska Institutet

Further studies are needed before the method can be used clinically. The next step is to test it in primary care, where the incidence of cancer is lower than in specialist care.

The research was funded by the Swedish Research Council, the Knut and Alice Wallenberg Foundation and the Jochnick Foundation, among others. 

 

Source:
Journal reference:

Wannberg, F.,  et al. (2025). Plasma protein profiling predicts cancer in patients with non-specific symptoms. Nature communications. doi: 10.1038/s41467-025-67688-3. https://www.nature.com/articles/s41467-025-67688-3

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New blood biomarker tracks brain injury progression after ischemic stroke